{"id":"doxercalciferol-capsules-hectorol-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Elevated calcium-phosphate product"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxercalciferol is a prodrug that is converted in the body to the active metabolite 1,25-dihydroxyvitamin D2, which binds to and activates the vitamin D receptor (VDR) in target tissues. This activation regulates intestinal calcium and phosphate absorption, bone mineralization, and suppresses parathyroid hormone (PTH) production, making it effective for treating secondary hyperparathyroidism in patients with chronic kidney disease.","oneSentence":"Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:59.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis"},{"name":"Secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease not on dialysis"}]},"trialDetails":[{"nctId":"NCT02859896","phase":"PHASE3","title":"Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-01-19","conditions":"Secondary Hyperparathyroidism-Chronic Kidney Disease","enrollment":21},{"nctId":"NCT00463021","phase":"PHASE4","title":"A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-04","conditions":"Secondary Hyperparathyroidism","enrollment":36},{"nctId":"NCT00418600","phase":"PHASE4","title":"A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-11","conditions":"Secondary Hyperparathyroidism","enrollment":36},{"nctId":"NCT00601107","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-04","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"doxercalciferol capsules, Hectorol® capsules","genericName":"doxercalciferol capsules, Hectorol® capsules","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, Secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease not on dialysis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}